Brian Gallagher, Jr has departed from a partner position at SR One, the corporate venture capital arm of pharmaceutical firm GlaxoSmithKline, to take the same position at investment group Abingworth.
Gallagher joined SR One in 2010 after two years as director and then senior director of corporate development for Sirtris Pharmaceuticals, a biotech developer acquired by GlaxoSmithKline for $720m.
During his time at SR One, Gallagher helped set up the unit’s Boston office, and will work in the Boston office of life sciences-focused Abingworth. He held board seats at SR One portfolio companies including River Vision Development, Dicerna and SpringLeaf Therapeutics.
Kurt von Emster, one of two managing partners at Abingworth’s Boston office, said: Boston is a key life science innovation centre and Brian’s extensive investment experience, network and business oversight will add significantly to the continued success and future of Abingworth.”
Photo of Brian Gallagher, Jr courtesy of Twitter.
